Five things for pharma marketers to know: Wednesday, September 30, 2020
California to attempt to develop generic drugs; Recovered COVID-19 patients in South Korea experienced side effects; Children make up 10% of coronavirus cases in the U.S.
Drug Pricing
COVID-19 kicks drug pricing down the road
The attention to the upcoming presidential election also dims the likelihood of legislation efforts until 2021.
Pharma industry, Trump publicly negotiate drug pricing rules
President Trump is putting pressure on the pharma industry ahead of the presidential election.
Five things for pharma marketers to know: Wednesday, August 26, 2020
Nursing home guidelines require testing for staff, residents; Justice Department to charge Teva in price-fixing probe; Verily launches subsidiary focused on stop-loss health insurance.
Pandemic or no, pharma needs to push drug pricing dialogue
Although the world is still months away from a COVID-19 vaccine, it’s imperative that pharma companies have the conversation right now about the cost of innoculation.
Five things for pharma marketers to know: Wednesday, August 5, 2020
Attorneys general calls on government to lower price of remdesivir; FDA finalizing CBD guidelines; Apple and UCLA begin depression and anxiety study.
Five things for pharma marketers to know: Wednesday, July 29, 2020
Advocates call on Facebook to control vaccine misinformation; Democratic lawmakers to investigate government’s role in developing remdesivir; Pfizer CEO criticizes Trump drug price orders.
Five things for pharma marketers to know: Monday, July 27, 2020
Opioid labels must include information about naloxone; Three of four Americans support mask requirements; Submit a cover design for the MM&M Hall of Femme issue.
‘Next remdesivir’ should cost below $1,000: patient poll
Ninety percent of patients said the price Gilead is charging for remdesivir is not affordable, and nearly three-quarters said that the next COVID-19 treatment or vaccine should cost no more than $999.
Five things for pharma marketers to know: Friday, July 10, 2020
Drug prices continue to rise; CDC won’t change school reopening guidelines; WHO says indoor airborne transmission of COVID-19 can’t be ruled out.
